Bioreductive and gene therapy approaches to hypoxic diseases

Advanced Drug Delivery Reviews

Volumn 53, Issue 2, 2001, Pages 217-228

  Jaffar, Mohammed ^a   Williams, Kaye J ^a   Stratford, Ian J ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Antibody directed enzyme prodrug therapy (ADEPT); Benzoquinone; Bioreductive; Delivery agents; Gene therapy; Gene directed enzyme prodrug therapy (GDEPT); HIF 1 ; Hypoxia; Hypoxia inducible factor (HIF); Hypoxia selectivity; Indolequinone; Ischaemia; Naphthoquinone; Nitroaromatic; Nitroheterocyclic; Nitroimidazole; Prodrugs; Quinone; Reductive activation; Reductive enzymes

Indexed keywords

GENES; ONCOLOGY; PATHOLOGY; PHYSIOLOGY;

BIOREDUCTIVE;

CONTROLLED DRUG DELIVERY;

AROMATIC NITRO COMPOUND; BENZOQUINONE; CARBONYL REDUCTASE; CYTOCHROME B5 REDUCTASE; DIHYDROLIPOAMIDE DEHYDROGENASE; FLUCYTOSINE; FLUOROURACIL; HYDROQUINONE; HYPOXIA INDUCIBLE FACTOR 1; INDOLEQUINONE; NAPHTHOQUINONE; PRODRUG; QUINONE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SEMIQUINONE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR HIF 1; UNCLASSIFIED DRUG; XANTHINE DEHYDROGENASE; XANTHINE OXIDASE;

CANCER CHEMOTHERAPY; DNA RESPONSIVE ELEMENT; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; ENZYME ACTIVATION; EXPRESSION VECTOR; GENE EXPRESSION REGULATION; GENE SEQUENCE; GENE TARGETING; GENE THERAPY; HUMAN; HYPOXIA; HYPOXIC CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REDUCTION; REVIEW; SOLID TUMOR; TARGET CELL;

ANIMALS; ANOXIA; GENE THERAPY; HUMANS; OXIDATION-REDUCTION; QUINONES;

EID: 0035904930     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(01)00228-9     Document Type: Review

References (69)

1. Tumour hypoxia: Definitions and current clinical, biological and molecular aspects
2. Causes and consequences of tumour acidity and implications for treatment
3. Hypoxia in tumours: A paradigm for the approach to biochemical and physiological heterogeneity
4. Hypoxia and molecular cardiovascular medicine
5. Excitotoxicity and neurodegenerative diseases
6. Influence of hypoxia in inflammatory synovitis
7. Intestinal motility during hypoxia and reoxygenation in vitro
8. Current therapies for wound healing: Electrical stimulation, biological therapeutics and the potential for gene therapy
9. Acute mountain sickness at 3500 and 4250 m. A study of symptom incidence and severity
10. Economy class travel
11. Hypoxic cells as specific targets for chemotherapy
12. Therapeutic targets in radiotherapy
13. DT-diaphorase: Possible roles in cancer chemotherapy and carcinogenesis
14. Relationship between NAD(P)H: Oxidoreductase 1 (NQO1) levels in a series of stably transfected cells and susceptibility to antitumour quinines
15. The relative importance of NADPH: Cytochrome c (P450) reductase for determining the sensitivity of human tumour cells to the indole quinone EO9 and related analogues lacking functionality at the C-2 and C-3 positions
16. Carbonyl reductase and NADPH cytochrome P450 reductase activities in human tumoral versus normal tissue
17. Reductive activation of mitomycin C by cytochrome b5 reductase
18. Phosphorylation of xanthine dehydrogenase/oxidase in hypoxia
19. Xanthine dehyrogenase and its role in cancer chemotherapy
20. Nitro reduction as an electronic switch for bioreductive drug activation
21. The sensitivity of human tumour cells to quinone bioreductive drugs: What role for DT-diaphorase?
22. Xanthine dehydrogenase/oxidase may protect ischemic heart from peroxinitrite mediated nitration
23. Hypoxia, oxidative stress and rheumatoid-arthritis
24. Bioreductive drugs: Selectivity towards hypoxic tissue
25. Bioreductive drugs into the next millennium
26. Electron transfer and oxidative stress as key factors in the design of drugs selectively active in hypoxia
27. The design of selectively-activated prodrugs for cancer chemotherapy
28. Targeting hypoxia with a new generation of indolequinones
29. Bioreductive therapies: An overview of drugs and their mechanism of action
30. Nitroheterocycle reduction as a paradigm for intramolecular catalysis of drug delivery to hypoxic cells
31. Self-immolative prodrugs - Candidates for antibody-directed enzyme prodrug therapy in conjunction with a nitroreductase enzyme
32. Bioreductively-activated prodrugs for targeting hypoxic tissue: Elimination of aspirin from 2-nitroimidazole derivatives
33. The 5-nitrofuran-2-ylmethylidene group as a potential bioreductively activated prodrug system for diol-containing drugs
34. N-substituted 2-(2,6-dinitrophenylamino)propanamides: Novel prodrugs that release a primary amine via nitroreduction and intramolecular cyclisation
35. Regiospecific reductive elimination of aspirin from indolequinones
36. Indolequinone antitumour agents: Reductive activation and elimination from (5-methoxy-1-methyl-4,7-dioxoindole-3-yl)methyl derivatives and hypoxia-selective cytotoxicity in vitro
37. Controlling the rates of reductively-activated elimination from the (indol-3-yl)methyl position of indolequinones
38. Development of novel quinone phosphoramidate prodrugs targeted to DT-diaphorase
39. Reductive lactonization of strategically methylated quinone propionic-acid esters and amides
40. Indolequinone bioreductive drugs: Kinetic factors which influence selectivity for hypoxia
41. Inducible operation of the erythropoietin 3′ enhancer in multiple cell lines: Evidence for a widespread oxygen-sensing mechanism
42. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia
43. 2 tension
44. Functional interference between hypoxia and dioxin signal transduction pathways: Competition for recruitment of the ARNT transcription factor
45. In vivo expression of mRNA's encoding hypoxia-inducible factor 1
46. 2 dependent degradation domain via the ubiquitin-proteosome pathway
47. Regulation of the hypoxia-inducible factor 1α by the ubiquitin-proteosome pathway
48. The tumour suppressor protein VHL targets hypoxia inducible factors for oxygen-dependent proteolysis
49. 2 sensing
50. 2-regulated prolyl hydroxylation
51. Hypoxia-inducible factor 1 modulates gene expression in solid tumours and influences both angiogenesis and tumour growth
52. V-src induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding VEGF and enolase 1: Involvement of HIF-1 in tumour progression
53. HIF-1α is required for solid tumour formation and embryonic vascularisation
54. Hypoxia-inducible factor 1α is a positive factor in solid tumour growth
55. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases
56. Overexpression of hypoxia-inducible factor 1α is a marker for an unfavourable prognosis in early-stage invasive cervical cancer
57. Gene transfer of antisense hypoxia-inducible factor-1α enhances the therapeutic efficacy of cancer immunotherapy
58. Suppression of tumour growth through disruption of hypoxia-inducible transcription
59. Angiogenesis is induced in a rabbit model of hindlimb ischaemia by naked DNA encoding an HIF-1α/VP16 hybrid transcription factor
60. Targeting gene expression to hypoxic tumour cells
61. Therapeutic efficacy of the suicide gene driven by the promoter of vascular endothelial growth factor gene against hypoxic tumour cells
62. Development of a novel enzyme/prodrug combination for gene therapy of cancer: Horseradish peroxidase/indole-3-acetic acid
63. Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cuclophosphomide for P450/P450-reductase-based cancer gene therapy
64. Overexpression of human NADPH: Cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR4233) and RSU1069
65. Characterisation of physiologically regulated vectors for the treatment of ischaemic disease
66. An adenoviral vector regulated by hypoxia for the treatment of ischaemic disease and cancer
67. Developing VDEPT for DT-diaphorase (NQO1) using AAV vector plasmid
68. Cancer chemotherapy: A pacitaxel prodrug for ADEPT (antibody-directed enzyme prodrug therapy)
69. Vascular endothelial growth-factor induced by hypoxia may mediate hypoxia-initiated angiogenesis